Loading...
Loading...
Janssen Research & Development,
LLC announced today that the U.S. Food and Drug Administration has
assigned a Priority Review designation to the supplemental New Drug
Application filed on December 29, 2011 for XARELTO^ (rivaroxaban), an
oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in
patients with Acute Coronary Syndrome.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in